Results for tag: "Optic Neuromyelitis Drug"

Optic Neuromyelitis (ON) is a rare neurological disorder that affects the optic nerve and spinal cord. It is characterized by inflammation of the optic nerve and spinal cord, resulting in vision loss and neurological deficits. Treatment of ON is typically focused on reducing inflammation and preventing further damage. Clinical trials are an important part of the development of new treatments for ON. These trials are designed to evaluate the safety and efficacy of potential treatments, as well as to identify any potential side effects. The Optic Neuromyelitis Drug market is a rapidly growing field, with a number of companies developing new treatments for ON. These companies are focused on developing treatments that are safe and effective, while also minimizing side effects. Companies in this market include Biogen, Novartis, and Merck, among others. Show Less Read more